|
Accession number;05A0015581
|
| Title;Up-to-date topics of Palivizumab |
| Author;
HARUNA SHIGENORI
(Abottojapan)
HITORA SHINTARO
(Abottojapan)
TAKADA KEISUKE
(Abottojapan)
|
Journal Title;Allergy in Practice
|
Journal Code:Z0246B
|
ISSN:0285-6379
|
|
VOL.;NO.327;PAGE.44-48(2005)
|
| Figure&Table&Reference;FIG.2, TBL.3, REF.12 |
| Pub. Country;Japan |
| Language;Japanese |
| Abstract;A RS virus (RSV) is mentioned as a main cause virus of the respiratory infection in the infancy, and it is liable to severe lower respiratory tract diseases such as the bronchiolitis, when child born prematurely and child with basal disease in lung and heart fall ill. Palivizumab is a anti-RS virus hominization monoclonal antibody which gene recombination created. Palivizumab is combined with antigen region called F protein siteA of RSV, and it neutralizes the infection of RSV by inhibiting the structural change of F protein necessary for membrane fusion, and duplicate and breeding of RSV are suppressed. Palivizumab is used by the clinic as the drug which suppresses the crisis of the severe lower respiratory tract disease by RSV of the high risk child in Europe and America since 1998. It is approved in Japan in 2002, and it has come to it in the present. Recently, the RSV bronchiolitis in the infancy is noticed as a factor of the repetitive stridor/asthma crisis after year. In suppressing the deterioration by RSV, the report in which Palivizumab is useful as the means which the stridor in the back year appears has been made. |
|
|
|
Related Articles;
|
